Dapagliflozin reduced the risk of death or worsening heart failure in older patients with aortic stenosis who underwent transcatheter aortic-valve implantation.

Adhering to the principles of evidence-based medicine, Venus Medtech has consistently conducted long-term follow-up studies ...

Inc. (Stock Code: 2500.HK, hereinafter referred to as 'Venus Medtech' or the 'Company'), a global leader in structural heart therapies, has announced financial results for the year ended December 31, ...

Aortic valve area was smaller and mean gradient were higher in patients treated with SAPIEN 3 THVs, supporting the findings from the post-hoc analysis of the LANDMARK trial. 7 The different design of ...

For young Indians grappling with aortic valve disease, the Ross procedure offers a lifeline—one that restores vitality ...

Adding Farxiga (dapagliflozin) to standard care significantly reduced the risk of death or worsening heart failure in older ...

The replacement system is launching into markets already served by repair devices, namely Edwards’ Pascal and Abbott’s ...

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system ...

CHICAGO — A transcatheter aortic valve implantation (TAVI) device developed specifically for the treatment for aortic regurgitation has met all the prespecified safety and efficacy goals ...

(JAMA Network Open) Real-world data showed that low-risk patients who underwent transcatheter aortic valve replacement (TAVR) had 1-year mortality and stroke rates of 4.6% and 2.6%, respectively.

making the heart have to pump harder to get blood through the valve and into the aorta. It can lead to complications like left ventricular hypertrophy (LVH), diastolic dysfunction, and diastolic heart ...